Table 5.
Results from the expert survey on (A) the identification of gaps in available test methods for evaluation of endocrine disrupters based on diseases/disorders of concern, and (B) proposals to fill testing and endpoint gaps with a focus on the Retinoid system [30].
| 5A. Ranking of disease/disorder with respect to the level of concern (e.g. severity of impact on life quality and rising prevalence in the population) in humans and the need to develop methods to predict their development | |
|---|---|
| Rank* | Disease/disorder |
| 1 | Thyroid-related/neurodevelopmental disorders |
| 2 | Metabolic disorders |
| 3 | Immune system related disorders |
| 5B. Priority of novel test methods or new endpoints to existing tests in order to cover retinoic acid signalling pathways | ||
|---|---|---|
| Rank | Test method/Endpoint | Comments |
| Average – high | RAR/RXR transactivation | |
| Average | Retinoid-relevant endpoints in in vivo TGs | |
| IATA for retinoic acid axis | ||
| weight gain, adipose tissue mass, lipid accumulation, retinoid level measurements | not specific markers for RAR/RXR signalling | |
| Low | EROD-activity in vivo | |
| Cyp1A expression of mRNA or protein in vivo | ||
| AhR transactivation | ||
* Ranking is from the highest concern (1) to the lower (10) in the whole survey. Rank 1 is the area where methods should be developed with highest priority.
RAR: Retinoic acid receptor, RXR: retinoid X receptor, TG: Test Guideline, IATA: Integrated Approaches to Testing and Assessment, EROD: Ethoxyresorufin-O-deethylase, AhR: Aryl hydrocarbon receptor.